HIF1A and renal carcinoma: Drugs that modulate HIFs that are currently being evaluated in clinical trials are OKN-007, EZN-2698; modulators of HIF-1α translation (irinotecan and topotecan which are also topoisomerase 1 inhibitors); HIF-1α degradation inducers (HDAC inhibitors such as vorinostat, panobinostat, belinostat, and romidepsin) and transcriptional activity inhibitors (PT2977 and PT2385 that which is evaluated in renal cancer) [37].